ZA202308676B - Compositions and methods for removing bio-synthetic nano-particles from bodily fluids - Google Patents

Compositions and methods for removing bio-synthetic nano-particles from bodily fluids

Info

Publication number
ZA202308676B
ZA202308676B ZA2023/08676A ZA202308676A ZA202308676B ZA 202308676 B ZA202308676 B ZA 202308676B ZA 2023/08676 A ZA2023/08676 A ZA 2023/08676A ZA 202308676 A ZA202308676 A ZA 202308676A ZA 202308676 B ZA202308676 B ZA 202308676B
Authority
ZA
South Africa
Prior art keywords
bio
synthetic nano
particles
compositions
methods
Prior art date
Application number
ZA2023/08676A
Inventor
Dipanjan Pan
Allan Doctor
Nivesh Mittal
Original Assignee
Kalocyte Inc
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalocyte Inc, Univ Maryland filed Critical Kalocyte Inc
Publication of ZA202308676B publication Critical patent/ZA202308676B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A61F2/064—Blood vessels with special features to facilitate anastomotic coupling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687—Chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

Bait and capture methods and compositions for removing bio-synthetic nano-particles from body fluids. Bio-synthetic nano-particles are baited with one-half of a bait and capture complex and lyophilized. The baited bio-synthetic nano-particle is reconstituted and administered to a subject for diagnostic or therapeutic purposes. To remove the bio-synthetic nano-particle from the body, the body fluid containing the baited bio-synthetic nano-article is contacted with the capture portion of the bait and capture complex. The body fluid from which the bio-synthetic nano-particles have been removed may be returned to the subject.
ZA2023/08676A 2021-03-11 2023-09-11 Compositions and methods for removing bio-synthetic nano-particles from bodily fluids ZA202308676B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163159547P 2021-03-11 2021-03-11
PCT/US2022/019872 WO2022192619A1 (en) 2021-03-11 2022-03-11 Compositions and methods for removing bio-synthetic nano-particles from bodily fluids
US17/692,289 US20220287984A1 (en) 2021-03-11 2022-03-11 Compositions and methods for removing bio-synthetic nano-particles from bodily fluids

Publications (1)

Publication Number Publication Date
ZA202308676B true ZA202308676B (en) 2024-04-24

Family

ID=83195350

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/08676A ZA202308676B (en) 2021-03-11 2023-09-11 Compositions and methods for removing bio-synthetic nano-particles from bodily fluids

Country Status (12)

Country Link
US (1) US20220287984A1 (en)
EP (1) EP4304654A1 (en)
JP (1) JP2024509957A (en)
KR (1) KR20230155462A (en)
CN (1) CN117500526A (en)
AU (1) AU2022232631A1 (en)
BR (1) BR112023018210A2 (en)
CA (1) CA3210619A1 (en)
IL (2) IL305814A (en)
MX (1) MX2023010613A (en)
WO (1) WO2022192619A1 (en)
ZA (1) ZA202308676B (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4169079A (en) * 1977-10-24 1979-09-25 Iwao Tabushi Polystyrene based polymers containing cyclodextrin derivatives, metal complexes of the same, and process for the production of the same
AU2003299730B2 (en) * 2002-12-20 2009-04-02 Momenta Pharmaceuticals, Inc. Glycan markers for diagnosing and monitoring disease
US8167871B2 (en) * 2009-02-25 2012-05-01 The Invention Science Fund I, Llc Device for actively removing a target cell from blood or lymph of a vertebrate subject
WO2014039533A2 (en) * 2012-09-04 2014-03-13 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
JP6807740B2 (en) * 2013-05-03 2021-01-06 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ Blood substitute composition and its usage
CN104877127B (en) * 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification
WO2016050210A1 (en) * 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 Multifunctionalized polyethylene glycol derivative and preparation method therefor
CN111134116B (en) * 2020-01-02 2021-10-26 中化化工科学技术研究总院有限公司 Emamectin benzoate water dispersible granule and preparation method thereof

Also Published As

Publication number Publication date
BR112023018210A2 (en) 2023-10-03
JP2024509957A (en) 2024-03-05
CA3210619A1 (en) 2022-09-15
US20220287984A1 (en) 2022-09-15
EP4304654A1 (en) 2024-01-17
KR20230155462A (en) 2023-11-10
MX2023010613A (en) 2023-09-20
IL305815A (en) 2023-11-01
WO2022192619A1 (en) 2022-09-15
IL305814A (en) 2023-12-01
CN117500526A (en) 2024-02-02
AU2022232631A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
MX2018004376A (en) Injectable neurosteroid formulations containing nanoparticles.
HK1152883A1 (en) Formulation and method for the prevention and treatment of bone metastases or other bone diseases
WO2012064881A3 (en) Hemodialysis access system
MX2022004012A (en) Catheter locking solution and catheter locking therapy.
MX2019013798A (en) Algorithmic approach for estimation of respiration and heart rates.
EP4338804A3 (en) Epinephrine spray formulations
JP2016513953A5 (en)
EP1658853A4 (en) Remedy for internal administration against cranial nerve diseases containing mesenchymal cells as the active ingredient
Nisi et al. Madelung's disease
ZA202308676B (en) Compositions and methods for removing bio-synthetic nano-particles from bodily fluids
SG11201900986YA (en) Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
Kuropatnicki et al. The beginnings of modern research on propolis in Poland
WO2019232203A3 (en) Methods and compositions to alleviate vascular permeability
Ghorpade Reactive perforating leprosy: pustular erythema nodosum leprosum with epidermal perforation and liberation of Mycobacterium leprae.
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
JP2006282634A (en) Preventing or treating agent for systemic inflammation response syndrome
AU2018263871A1 (en) Tumor vs. matched normal cfRNA
WO2013016349A3 (en) Vessel treatment methods and devices for use in a graft device
MD3619G2 (en) Nasal remedy possessing vasoconstrictive and anti-edematous action
WO2009143478A3 (en) Efficient wellbeing assessment and improved treatment protocol
Oluranti et al. Prophylactic effects of some Nigerian higher fungi on malaria parasite, Plasmodium berghei berghei in BALB/c strain albino mice
CN111701012A (en) Application of IL-12 in postoperative antitumor aspect
Capps THE ARSENICAL TREATMENT OF CHRONIC INFECTIOUS ENDOCARDITIS.
Onyango Electrocardiography may be a useful tool in the diagnosis of early mild canine heartworm disease
RU2314572C2 (en) Method for infecting guinea pigs at studying biological properties of tuberculosis mycobacteria